The U.S. Food and Drug Administration (FDA) granted initial approval for Dapagliflozin (ANDA 211478) on April 6, 2026. This approval signifies the availability of a generic version of the drug, with MSN listed as the sponsor.
Background
This approval for Dapagliflozin is an Abbreviated New Drug Application (ANDA 211478), granted by the FDA on April 6, 2026. An ANDA approval indicates that the generic drug is bioequivalent to its brand-name counterpart, meaning it works in the same way and provides the same clinical benefit. Dapagliflozin is the active ingredient in medications known by brand names such as Farxiga and Xigduo XR. The sponsor for this specific generic approval is MSN.
What this means
The initial FDA approval of generic Dapagliflozin on April 6, 2026, represents a significant step towards increasing patient access to this important medication. Generic drugs are typically more affordable than their brand-name versions, which can lead to substantial cost savings for patients, healthcare systems, and insurers. This increased affordability can improve medication adherence and overall public health outcomes for individuals who require Dapagliflozin for their treatment. The entry of a generic version, sponsored by MSN, expands the competitive landscape in the pharmaceutical market, potentially driving down prices further and making essential therapies more accessible to a broader patient population.
Source
The information regarding this initial FDA approval was obtained from the U.S. Food and Drug Administration's database of approved drug products. The approval for Dapagliflozin (ANDA 211478) was recorded on April 6, 2026, on accessdata.fda.gov.